Matt Hewett

Matt Hewett questioned the historical timeframe for new clinical customers to ramp up from low to higher volume purchases, given the recent decrease in average revenue per customer due to new additions. He also asked about the impact of government initiatives to shorten drug development timelines on Teknova's business model.

Answer

Stephen Gunstream, President and CEO, explained that the ramp-up time is therapy-dependent, with early-phase customers lowering the average revenue per customer. He noted that spend increases significantly in later phases (e.g., Phase 2 customers spending hundreds of thousands). Mr. Gunstream stated that shorter drug development timelines would be a significant tailwind, especially for breakthrough or rare disease designations. He emphasized Teknova's strong position in early-stage development due to its ability to provide small batches of custom formulations and scale through commercialization.

Matt Hewett inquired about the potential for BioLife Solutions' CryoCase product to reduce scrap and improve long-term margins, particularly in light of the bag yield issues experienced in the second half of 2025. He also asked about the comprehensiveness of the Qkine collaboration and the potential for future agreements or M&A activity involving other commonly used cytokines and growth factors.

Answer

Chairman and CEO Roderick de Greef clarified that CryoCase is designed for the final product to the patient, while a new rigid container (RCC) is being developed to replace bags for shipping product from BioLife to customers, addressing the bag yield problem. He noted the RCC is 18-24 months away, with current remediation being process-oriented. Regarding Qkine, Mr. de Greef confirmed the deal has specific exclusivity for certain cytokines, with broader non-exclusive access, and indicated that this is a first step, with potential for the relationship to evolve and for future agreements or M&A in the cytokine space.

Matt Hewett asked if expense lines have reset after the earlier-than-expected restructuring, inquiring if Q4 numbers reflect the new baseline for normalized growth or if another step down is expected after Q1. He also asked for thoughts on recent FDA draft guidance and its potential benefits.

Answer

Rajesh Asarpota (CFO) confirmed the $65 million in expense reductions, stating that labor and facilities expenses will remain stable, while controllable expenses will be significantly lower, with a modest drop expected in Q1. Bernd Brust (CEO) stated the company has not closely reviewed the FDA draft guidance and lacks a clear viewpoint, noting low exposure to vaccine-related policy changes.